{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,22]],"date-time":"2024-09-22T16:10:06Z","timestamp":1727021406656},"reference-count":26,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,22]]},"DOI":"10.7759\/cureus.69918","type":"journal-article","created":{"date-parts":[[2024,9,22]],"date-time":"2024-09-22T15:30:17Z","timestamp":1727019017000},"source":"Crossref","is-referenced-by-count":0,"title":["Inclisiran: A Systematic Review Exploring the Revolutionary Approach of Twice-Yearly Dosing Regimen in the Treatment of Hypercholesterolemia"],"prefix":"10.7759","author":[{"given":"Sanjana","family":"Singareddy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Surakchhya","family":"Dhakal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Therese Anne","family":"Limba\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vignesh","family":"Murugan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farhana","family":"Nazmin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Safeera","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1076-7460.2007.04886.x","article-title":"Contemporary diagnosis and management of hypercholesterolemia in elderly acute myocardial infarction patients: a population-based study","volume":"16","author":"Berger AK","year":"2007","unstructured":"Berger AK, Duval SJ, Armstrong C, Jacobs DR Jr, Luepker RV. Contemporary diagnosis and management of hypercholesterolemia in elderly acute myocardial infarction patients: a population-based study. Am J Geriatr Cardiol. 2007, 16:15-23. 10.1111\/j.1076-7460.2007.04886.x","journal-title":"Am J Geriatr Cardiol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32203-7","article-title":"Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","year":"2018","unstructured":"Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017. a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018, 392:1736-88. 10.1016\/S0140-6736(18)32203-7","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000757","article-title":"Heart Disease and Stroke Statistics-2020 update: a report from the American Heart Association","volume":"141","author":"Virani SS","year":"2020","unstructured":"Virani SS, Alonso A, Benjamin EJ, et al.. Heart Disease and Stroke Statistics-2020 update: a report from the American Heart Association. Circulation. 2020, 141:e139-596. 10.1161\/CIR.0000000000000757","journal-title":"Circulation"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001123","article-title":"Heart Disease and Stroke Statistics-2023 update: a report from the American Heart Association","volume":"147","author":"Tsao CW","year":"2023","unstructured":"Tsao CW, Aday AW, Almarzooq ZI, et al.. Heart Disease and Stroke Statistics-2023 update: a report from the American Heart Association. Circulation. 2023, 147:e93-e621. 10.1161\/CIR.0000000000001123","journal-title":"Circulation"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e3182160726","article-title":"Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association","volume":"123","author":"Miller M","year":"2011","unstructured":"Miller M, Stone NJ, Ballantyne C, et al.. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011, 123:2292-333. 10.1161\/CIR.0b013e3182160726","journal-title":"Circulation"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0106-z","article-title":"Atherosclerosis","volume":"5","author":"Libby P","year":"2019","unstructured":"Libby P, Buring JE, Badimon L, et al.. Atherosclerosis. Nat Rev Dis Primers. 2019, 5:56. 10.1038\/s41572-019-0106-z","journal-title":"Nat Rev Dis Primers"},{"key":"ref7","article-title":"Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report","volume":"106","year":"2002","unstructured":"Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002, 106.3143-421.","journal-title":"Circulation"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.01.027","article-title":"Apolipoprotein B and non-HDL cholesterol better reflect residual risk than LDL cholesterol in statin-treated\u00a0patients","volume":"77","author":"Johannesen CD","year":"2021","unstructured":"Johannesen CD, Mortensen MB, Langsted A, Nordestgaard BG. Apolipoprotein B and non-HDL cholesterol better reflect residual risk than LDL cholesterol in statin-treated\u00a0patients. J Am Coll Cardiol. 2021, 77:1439-50. 10.1016\/j.jacc.2021.01.027","journal-title":"J Am Coll Cardiol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-022-01721-y","article-title":"Distribution of lipid levels and prevalence of hyperlipidemia: data from the NHANES 2007-2018","volume":"21","author":"Li Z","year":"2022","unstructured":"Li Z, Zhu G, Chen G, Luo M, Liu X, Chen Z, Qian J. Distribution of lipid levels and prevalence of hyperlipidemia: data from the NHANES 2007-2018. Lipids Health Dis. 2022, 21:111. 10.1186\/s12944-022-01721-y","journal-title":"Lipids Health Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2022.101658","article-title":"Approach to patients with elevated low-density lipoprotein cholesterol levels","volume":"37","author":"Feingold KR","year":"2023","unstructured":"Feingold KR, Chait A. Approach to patients with elevated low-density lipoprotein cholesterol levels. Best Pract Res Clin Endocrinol Metab. 2023, 37:101658. 10.1016\/j.beem.2022.101658","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad266","article-title":"Great debate: in patients with decompensated heart failure, acetazolamide in addition to loop diuretics is the first choice","volume":"44","author":"Mullens W","year":"2023","unstructured":"Mullens W, Schulze PC, Westphal J, Bogoviku J, Bauersachs J. Great debate: in patients with decompensated heart failure, acetazolamide in addition to loop diuretics is the first choice. Eur Heart J. 2023, 44:2159-69. 10.1093\/eurheartj\/ehad266","journal-title":"Eur Heart J"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615758","article-title":"Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol","volume":"376","author":"Ray KK","year":"2017","unstructured":"Ray KK, Landmesser U, Leiter LA, et al.. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017, 376:1430-40. 10.1056\/NEJMoa1615758","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2019.3502","article-title":"Effect of 1 or 2 doses of inclisiran on low-density lipoprotein cholesterol levels: one-year follow-up of the ORION-1 randomized clinical trial","volume":"4","author":"Ray KK","year":"2019","unstructured":"Ray KK, Stoekenbroek RM, Kallend D, et al.. Effect of 1 or 2 doses of inclisiran on low-density lipoprotein cholesterol levels: one-year follow-up of the ORION-1 randomized clinical trial. JAMA Cardiol. 2019, 4:1067-75. 10.1001\/jamacardio.2019.3502","journal-title":"JAMA Cardiol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(22)00353-9","article-title":"Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial","volume":"11","author":"Ray KK","year":"2023","unstructured":"Ray KK, Troquay RP, Visseren FL, et al.. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial. Lancet Diabetes Endocrinol. 2023, 11:109-19. 10.1016\/S2213-8587(22)00353-9","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray KK","year":"2020","unstructured":"Ray KK, Wright RS, Kallend D, et al.. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020, 382:1507-19. 10.1056\/NEJMoa1912387","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.122.063460","article-title":"Efficacy, safety, and tolerability of inclisiran in patients with homozygous familial hypercholesterolemia: results from the ORION-5 randomized clinical trial","volume":"149","author":"Raal F","year":"2024","unstructured":"Raal F, Durst R, Bi R, Talloczy Z, Maheux P, Lesogor A, Kastelein JJ. Efficacy, safety, and tolerability of inclisiran in patients with homozygous familial hypercholesterolemia: results from the ORION-5 randomized clinical trial. Circulation. 2024, 149:354-62. 10.1161\/CIRCULATIONAHA.122.063460","journal-title":"Circulation"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the treatment of heterozygous familial hypercholesterolemia","volume":"382","author":"Raal FJ","year":"2020","unstructured":"Raal FJ, Kallend D, Ray KK, et al.. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med. 2020, 382:1520-30. 10.1056\/NEJMoa1913805","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvae109","article-title":"Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial","volume":"4","author":"Wright RS","year":"2024","unstructured":"Wright RS, Raal FJ, Koenig W, et al.. Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial. Cardiovasc Res. 2024, 4:14-6. 10.1093\/cvr\/cvae109","journal-title":"Cardiovasc Res"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2023.04.010","article-title":"The clinical effects of inclisiran, a first-in-class LDL-C lowering siRNA therapy, on the LDL-C levels in Chinese patients with hypercholesterolemia","volume":"17","author":"Luo Z","year":"2023","unstructured":"Luo Z, Huang Z, Sun F, et al.. The clinical effects of inclisiran, a first-in-class LDL-C lowering siRNA therapy, on the LDL-C levels in Chinese patients with hypercholesterolemia. J Clin Lipidol. 2023, 17:392-400. 10.1016\/j.jacl.2023.04.010","journal-title":"J Clin Lipidol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.5551\/jat.64454","article-title":"Efficacy, safety, and pharmacokinetics of inclisiran in Japanese patients: results from ORION-15","volume":"31","author":"Yamashita S","year":"2024","unstructured":"Yamashita S, Kiyosue A, Maheux P, et al.. Efficacy, safety, and pharmacokinetics of inclisiran in Japanese patients: results from ORION-15. J Atheroscler Thromb. 2024, 31:876-903. 10.5551\/jat.64454","journal-title":"J Atheroscler Thromb"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacasi.2023.09.006","article-title":"Efficacy and safety of inclisiran in Asian\u00a0patients: results from ORION-18","volume":"4","author":"Huo Y","year":"2024","unstructured":"Huo Y, Lesogor A, Lee CW, et al.. Efficacy and safety of inclisiran in Asian\u00a0patients: results from ORION-18. JACC Asia. 2024, 4:123-34. 10.1016\/j.jacasi.2023.09.006","journal-title":"JACC Asia"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/diseases6030063","article-title":"Inclisiran: a new promising agent in the management of hypercholesterolemia","volume":"6","author":"Kosmas CE","year":"2018","unstructured":"Kosmas CE, Mu\u00f1oz Estrella A, Sourlas A, Silverio D, Hilario E, Montan PD, Guzman E. Inclisiran: a new promising agent in the management of hypercholesterolemia. Diseases. 2018, 6:4-6. 10.3390\/diseases6030063","journal-title":"Diseases"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-021-00936-1","article-title":"The role of RNA-targeted therapeutics to reduce ASCVD risk: what have we learned recently?","volume":"23","author":"Miname MH","year":"2021","unstructured":"Miname MH, Rocha VZ, Santos RD. The role of RNA-targeted therapeutics to reduce ASCVD risk: what have we learned recently?. Curr Atheroscler Rep. 2021, 23:40. 10.1007\/s11883-021-00936-1","journal-title":"Curr Atheroscler Rep"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22115880","article-title":"PCSK9 biology and its role in atherothrombosis","volume":"22","author":"Barale C","year":"2021","unstructured":"Barale C, Melchionda E, Morotti A, Russo I. PCSK9 biology and its role in atherothrombosis. Int J Mol Sci. 2021, 22:42-4. 10.3390\/ijms22115880","journal-title":"Int J Mol Sci"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3390\/ph16040577","article-title":"Inclisiran, low-density lipoprotein cholesterol and lipoprotein (a)","volume":"16","author":"Katsiki N","year":"2023","unstructured":"Katsiki N, Vrablik M, Banach M, Gouni-Berthold I. Inclisiran, low-density lipoprotein cholesterol and lipoprotein (a). Pharmaceuticals (Basel). 2023, 16:32-4. 10.3390\/ph16040577","journal-title":"Pharmaceuticals (Basel)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/290303-inclisiran-a-systematic-review-exploring-the-revolutionary-approach-of-twice-yearly-dosing-regimen-in-the-treatment-of-hypercholesterolemia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,22]],"date-time":"2024-09-22T15:30:19Z","timestamp":1727019019000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/290303-inclisiran-a-systematic-review-exploring-the-revolutionary-approach-of-twice-yearly-dosing-regimen-in-the-treatment-of-hypercholesterolemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,22]]},"references-count":26,"URL":"https:\/\/doi.org\/10.7759\/cureus.69918","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,22]]}}}